Fabry nephropathy and the case for adjunctive renal therapy.
Wanner
Christoph
C
Breunig
Frank
F
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000795:Fabry Disease / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D000519:alpha-Galactosidase / Q000627:therapeutic use*
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D011994:Recombinant Proteins; D000519:alpha-Galactosidase